Trump Speech on Plan for Lower Drug Prices 5/11 After close. Biotech and healthcare stocks were broadly higher. Key words by HHS Secretary were “complex” and “will take time”; more updates tomorrow. General objectives appear to be to lower list prices and squeeze middlemen like PBMs, offer Part-D type discount with Part-B drugs and promote […]
Update 4/30… Vertex Pharmaceuticals (VRTX) Beat Consensus by 4% Financial Results: CF Revenues rose 33% Q’18 o Q’17 from $481M to $638M; GAAP net income down 15% ,$210M from $241M. Two Phase 3 triple combination clinical development programs are underway : VX-559 and VX-441 best for 2020 launch as well as pain and sickle cell R&D. […]
Update-1 …2/17/18 Good Week for Biotech: FBT up 6.29%, IBB up 4.44%, XBI up 6.26% Biotech stocks continued their strong recovery from the big sell-off in the prior week but about 3% under 2018 highs. Biotech ETFs tracked the QQQ up 5.68% for the week but biotech stocks are leaders YTD beating the S&P 500. […]
Large Cap Biopharmaceuticals Performance Part 1- After Correction Technicals: we are holding the December 2017 bottom but 2018 gains on some indices have been wiped out with peak values on Jan. 26. The FBT was the top performing ETF in 2018 YTD. Many of our picks have outperformed the market. Here are some metrics on […]
Updates-2… 2/6/18 Biotechs Down With Overall Market Over 5 Days Closing Prices as of 2/6/18 XBI up 3% at $91.05 down 5.34% over 5 days IBB up 2% at $109.36 down 7.35% over 5 days QQQ up 2.65% at $162.31 down 5.04% over 5 days By now you have read about all the possible reasons […]
2/28/18 Update Tape looks sluggish at major resistance. Downgrade to HOLD on Celgene (CELG). Bad regulatory news on relapsing multiple sclerosis drug ozanimod. 2/2/18 Update After Sell-Off Cautious on Amgen (AMGN) after earnings release but looks better than the IBB if you are bullish on biotech. XBI remains a top ETF pick but given weak […]
Clinical Diagnostics and Tools: Big Winners Are In Genomics and Personalized Medicine Slower growth in routine clinical diagnostics, tools are favored. Hologic has a unique business model for women’s health and diagnostics. Gene sequencing is important for future clinical applications and biopharma R&D. We haven’t updated our Clinical Diagnostics and Tools Portfolio since the severe […]
MegaCap Tech Stocks Take a Big Hit-Volatility Rising in a Sector Shift Market Rotation Supports Overall Market-S&P 500 Stable today up 17% YTD Sluggish Biotech Now Just a Market Performer With IBB up 17% YTD The booming tech sector sold off today with the XLK down over 2%. Harder hit were the 2017 high fliers […]
11/29/17 Market Reversal in Early Trading 11:35a -FAANG sell-off Stocks show a rotation out of technology and into financials and cyclical consumer goods. XLK is down 2.2%, XLV up 0.66%, IBB up 0.42% with large caps holding. 11/28/17 Biotechs Treading Water But Many Good Opportunities Exist Biotechs show a lack of momentum but are holding […]
Biotech Correction: Sell-Off Has Reached 10% over Three Months Biotechs under pressure-has revenue growth slowed? Technicals-a break through bottom channel. Need a bounce today. Celgene is a bellwether. A buy in the $102 range. Biotech stocks have been weak since Q4 earnings were reported and despite gains of about 15% or more year-to-date (IBB), warning […]
PO Box 3701
Manhattan Beach CA 90266
(310) 871-1231
rod@rayno.com
Rod Raynovich is the founder of Raygent Associates, a management consulting firm providing business development and strategic marketing services in the life science and medical device area. He publishes his thoughts and analysis on the biotech industry at www.raygent.com.